Citius Pharmaceuticals Reports Expected Milestones
Citius Pharmaceuticals Reports Expected Milestones
citius pharmaceuticals報告了預期的里程碑
- Multiple catalysts for potentially transformative assets in second half of 2024
- Strong momentum expected from positive topline results of Phase 3 Mino-Lok trial, commercialization of LYMPHIR if approved
- First-and-only advantage for Mino-Lok with no current FDA-approved or investigational products; LYMPHIR expected to be additive to current treatment options with mechanism of action supporting market advantage
- Financial platform and pending oncology spin-off support pipeline development and investment in long-term growth
- Clinical and operational achievements offer powerful levers for value creation
- National Sales Director onboarded to recruit and lead the sales organization in preparation for anticipated launch of LYMPHIR
- 2024年下半年有多個可能具有變革性的資產催化劑。
- 如果LYMPHIR經過批准，第三階段Mino-Lok試驗的積極頂線結果和LYMPHIR的商業化預計將有強勁的勢頭。
- Mino-Lok擁有首創和獨特的優勢，目前無任何經FDA批准或正在研究的成品；LYMPHIR預計將成爲當前治療選項的補充，其作用機制支持市場優勢。
- 資金平台和即將宣佈的腫瘤分拆支持公司長期增長和貸款管道的開發。
- 臨床和運營成就爲創造價值提供了有力的槓桿。
- 全國銷售主管加入公司招募並領導銷售機構，爲預期的LYMPHIR發行做準備。
譯文內容由第三人軟體翻譯。
以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。